Drugs / Boswellia serrata extract
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT07867158 | Oct 2026 → Apr 2027 expected | prostate cancer | Brigham and Women's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT00243022 | Sep 2004 → Mar 2010 | brain edema, central nervous system neoplasm | Ali Altunkaya | Terminated | Missed primary Stop: Enrollment |
| Phase not applicable1 trial | ||||||
| — | NCT05345028 | Mar → May 2021 | acute diarrhea | Azienda di Servizi alla Persona di Pavia | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Boswellia serrata extract | “Positive Effects of a Lecithin-based Delivery Form of Boswellia Serrata Extract in Acute Diarrhea of Adult Subjects” NCT05345028 ↗ |
| Action | Inhibit | “a herbal preparation that inhibits 5-LO activity” NCT00243022 ↗ |
| Route | Oral | “given orally” NCT00243022 ↗ |